Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
- PMID: 26598758
- DOI: 10.1200/JCO.2015.62.8537
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
Comment in
-
Reply to A. Addeo and A. Bahl.J Clin Oncol. 2016 Feb 1;34(4):387-8. doi: 10.1200/JCO.2015.64.6562. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598756 No abstract available.
Comment on
-
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800753 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources